<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426737</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237ACH02T</org_study_id>
    <nct_id>NCT01426737</nct_id>
  </id_info>
  <brief_title>The Swiss Glucose Variability Study</brief_title>
  <official_title>The Swiss Glucose Variability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore long term glucose variability of a combination
      therapy of metformin and vildagliptin compared to a metformin - gliclazide combination.

      Multicenter, randomized, open, parallel group, Phase IV study, of 18 months duration.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).</measure>
    <time_frame>48h</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female patients aged =30 -= 75 years.

          2. History of type 2 diabetes for at least 6 months.

          3. Patients inadequately controlled (i.e. not reaching target) with maximum tolerated
             doses of metformin with HbA1c of 6.5-9.0%.

          4. Patients inadequately controlled (i.e. not reaching target) with maximum tolerated
             doses of metformin with a body mass index (BMI) of 25-40 kg/m2.

          5. Patients that are currently treated with metformin, gliclazide or both but not with
             other glucose lowering agents.

          6. Outpatient.

          7. If female of childbearing potential: Will to practice reliable birth control measures
             [e.g., surgical sterilization, hormonal contraception, double-barrier methods (any
             double combination of IUD, male or female condom with spermicidal gel, diaphragm,
             sponge, cervical cap)] during study treatment and for at least 28 days after
             completion of study medication; not lactating or pregnant; and has a documented
             negative pregnancy test result at baseline.

        Exclusion criteria:

          1. Type 1 diabetes as defined by the American Diabetes Association (ADA).

          2. Type 2 diabetes currently (last 3 months) treated with insulin or glitazones.

          3. Acute or chronic diseases causing tissue hypoxia such as:

               -  cardiac or respiratory insufficiency

               -  myocardial infarct within the last 6 months

          4. Active liver disease with alanine aminotransferase (ALAT) and / or aspartate
             aminotransferase (ASAT) &gt; 3 x upper limit of normal.

          5. Relevant kidney disease such as :

               -  serum creatinine =133 µmol/l in males and &gt; 124 µmol/l in females

               -  proteinuria &gt; 300 mg/l

               -  status post kidney transplantation

               -  severe infection

               -  intravascular administration of contrast medium containing iod within the last 7
                  days

          6. Severe neuropathy (vibration perception at the base of the big toes &lt;2/8).

          7. Active proliferative diabetic retinopathy.

          8. Any clinically relevant major organ system disease including mental illnesses

          9. History of malignancy

         10. Pancreatitis

         11. Porphyria

         12. Severe disturbances of the adrenal gland

         13. Severe disturbances of the thyroid gland

         14. Allergy to vildagliptin or one of the excipients

         15. Allergy to metformin or one of the excipients

         16. Allergy to gliclazide, sulfonylurea or sulfonamides or one of the excipients.

         17. Drug or alcohol abuse.

         18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive pregnancy test (serum or urine).

         19. Any other condition that could interfere with the participation in the study according
             to the study protocol or with the ability to cooperate and comply with the study
             procedures.

         20. Treatment with any investigational drug, within 30 days or 5 half-lives before
             screening, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <phone>+41 (0)44 255 11 11</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Universitiy Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

